In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From EOC Pharma Group

The Journey Has Just Begun For LAG-3 Therapeutics

Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.

Innovation Research & Development

Aadi Starts Small With Fyarro, But Has Tumor-Agnostic Strategy In Mind

The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.

Approvals Cancer

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Deals Business Strategies

Baby-Wipes Maker Nutek Cites Contamination Risk In Nationwide Recall

Nutek withdraws a slew of baby-wipe brands sold through Walgreens, Family Dollar, Diapers.com and other retailers due to possible contamination with B. cepacia bacteria, a potentially serious infection threat to immunocompromised individuals and sufferers of cystic fibrosis in particular.

Consumer United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register